AAPL333.74+0.48 (+0.14%) ▲|ABBV254.49+0.10 (+0.04%) ▲|ABT100.68+1.85 (+1.87%) ▲|ACN143.57-1.04 (-0.72%) ▼|ADBE237.25+1.94 (+0.82%) ▲|AMAT529.66-31.27 (-5.57%) ▼|AMD495.76-5.18 (-1.03%) ▼|AMGN366.29-5.29 (-1.42%) ▼|AMT170.06+1.14 (+0.67%) ▲|AMZN247.23-2.66 (-1.06%) ▼|AVGO370.83-3.63 (-0.97%) ▼|AXP355.35-6.22 (-1.72%) ▼|BA214.03-0.31 (-0.14%) ▼|BAC61.27-0.22 (-0.36%) ▼|BKNG181.68-2.93 (-1.59%) ▼|BLK1,072.20-14.85 (-1.37%) ▼|BMY60.74+0.23 (+0.38%) ▲|BNY157.13-3.73 (-2.32%) ▼|BRK-B490.91-2.21 (-0.45%) ▼|C129.36-2.35 (-1.78%) ▼|CAT880.28+3.11 (+0.35%) ▲|CL92.98-1.09 (-1.16%) ▼|CMCSA23.79-0.31 (-1.29%) ▼|COF208.03-3.90 (-1.84%) ▼|COP114.71+1.87 (+1.66%) ▲|COST940.87-4.70 (-0.50%) ▼|CRM170.77-1.91 (-1.11%) ▼|CSCO111.94+2.28 (+2.08%) ▲|CVS107.47+0.97 (+0.91%) ▲|CVX187.38+3.52 (+1.91%) ▲|DE597.24-1.73 (-0.29%) ▼|DHR203.83-1.18 (-0.58%) ▼|DIS97.67-2.04 (-2.05%) ▼|DUK125.01-1.10 (-0.87%) ▼|EMR139.54+0.46 (+0.33%) ▲|FDX312.98-5.22 (-1.64%) ▼|GD368.58-0.24 (-0.07%) ▼|GE348.83+3.10 (+0.90%) ▲|GEV1,057.84+21.62 (+2.09%) ▲|GILD134.28-2.02 (-1.48%) ▼|GM76.07-1.65 (-2.12%) ▼|GOOG346.12-7.69 (-2.17%) ▼|GOOGL346.77-7.69 (-2.17%) ▼|GS1,065.22-30.24 (-2.76%) ▼|HD338.87-9.15 (-2.63%) ▼|HON225.02-1.31 (-0.58%) ▼|IBM212.67-6.38 (-2.91%) ▼|INTC95.04-1.94 (-2.00%) ▼|INTU291.09-3.70 (-1.26%) ▼|ISRG345.42-56.91 (-14.15%) ▼|JNJ253.04+3.07 (+1.23%) ▲|JPM341.10-2.05 (-0.60%) ▼|KO81.56-3.36 (-3.96%) ▼|LIN513.22-7.52 (-1.44%) ▼|LLY1,179.11+9.94 (+0.85%) ▲|LMT508.77-4.75 (-0.93%) ▼|LOW208.73-7.43 (-3.44%) ▼|LRCX313.30-7.66 (-2.39%) ▼|MA543.60-7.94 (-1.44%) ▼|MCD267.71-5.75 (-2.10%) ▼|MDLZ61.00-0.42 (-0.68%) ▼|MDT83.20-0.36 (-0.43%) ▼|META646.01-18.53 (-2.79%) ▼|MMM159.84-1.93 (-1.19%) ▼|MO74.21+1.18 (+1.62%) ▲|MRK127.50-0.13 (-0.10%) ▼|MS215.50-2.87 (-1.31%) ▼|MSFT393.82-7.28 (-1.82%) ▼|MU848.95-4.25 (-0.50%) ▼|NEE88.80-0.55 (-0.62%) ▼|NFLX68.95-5.40 (-7.26%) ▼|NKE43.76-0.81 (-1.82%) ▼|NOW103.24-0.77 (-0.74%) ▼|NVDA202.81-4.59 (-2.21%) ▼|ORCL126.41+2.20 (+1.77%) ▲|PEP137.12-2.31 (-1.66%) ▼|PFE25.05-0.09 (-0.36%) ▼|PG149.98-1.52 (-1.00%) ▼|PLTR132.38-2.06 (-1.53%) ▼|PM192.98+3.14 (+1.65%) ▲|QCOM171.78+1.11 (+0.65%) ▲|RTX193.51-0.85 (-0.44%) ▼|SBUX105.49-2.88 (-2.66%) ▼|SCHW101.56-1.24 (-1.21%) ▼|SO95.30-0.77 (-0.80%) ▼|SPG228.70+0.21 (+0.09%) ▲|T21.81-0.17 (-0.77%) ▼|TMO532.48-10.71 (-1.97%) ▼|TMUS192.43-0.42 (-0.22%) ▼|TSLA380.84-10.22 (-2.61%) ▼|TXN284.02-7.20 (-2.47%) ▼|UBER72.46-1.58 (-2.13%) ▼|UNH426.09+2.71 (+0.64%) ▲|UNP301.75+2.33 (+0.78%) ▲|UPS117.72+0.54 (+0.46%) ▲|USB63.14-0.87 (-1.36%) ▼|V358.56-6.58 (-1.80%) ▼|VZ43.59-0.29 (-0.66%) ▼|WFC87.51-0.56 (-0.64%) ▼|WMT114.24-0.71 (-0.62%) ▼|XOM147.36+1.41 (+0.97%) ▲|AAPL333.74+0.48 (+0.14%) ▲|ABBV254.49+0.10 (+0.04%) ▲|ABT100.68+1.85 (+1.87%) ▲|ACN143.57-1.04 (-0.72%) ▼|ADBE237.25+1.94 (+0.82%) ▲|AMAT529.66-31.27 (-5.57%) ▼|AMD495.76-5.18 (-1.03%) ▼|AMGN366.29-5.29 (-1.42%) ▼|AMT170.06+1.14 (+0.67%) ▲|AMZN247.23-2.66 (-1.06%) ▼|AVGO370.83-3.63 (-0.97%) ▼|AXP355.35-6.22 (-1.72%) ▼|BA214.03-0.31 (-0.14%) ▼|BAC61.27-0.22 (-0.36%) ▼|BKNG181.68-2.93 (-1.59%) ▼|BLK1,072.20-14.85 (-1.37%) ▼|BMY60.74+0.23 (+0.38%) ▲|BNY157.13-3.73 (-2.32%) ▼|BRK-B490.91-2.21 (-0.45%) ▼|C129.36-2.35 (-1.78%) ▼|CAT880.28+3.11 (+0.35%) ▲|CL92.98-1.09 (-1.16%) ▼|CMCSA23.79-0.31 (-1.29%) ▼|COF208.03-3.90 (-1.84%) ▼|COP114.71+1.87 (+1.66%) ▲|COST940.87-4.70 (-0.50%) ▼|CRM170.77-1.91 (-1.11%) ▼|CSCO111.94+2.28 (+2.08%) ▲|CVS107.47+0.97 (+0.91%) ▲|CVX187.38+3.52 (+1.91%) ▲|DE597.24-1.73 (-0.29%) ▼|DHR203.83-1.18 (-0.58%) ▼|DIS97.67-2.04 (-2.05%) ▼|DUK125.01-1.10 (-0.87%) ▼|EMR139.54+0.46 (+0.33%) ▲|FDX312.98-5.22 (-1.64%) ▼|GD368.58-0.24 (-0.07%) ▼|GE348.83+3.10 (+0.90%) ▲|GEV1,057.84+21.62 (+2.09%) ▲|GILD134.28-2.02 (-1.48%) ▼|GM76.07-1.65 (-2.12%) ▼|GOOG346.12-7.69 (-2.17%) ▼|GOOGL346.77-7.69 (-2.17%) ▼|GS1,065.22-30.24 (-2.76%) ▼|HD338.87-9.15 (-2.63%) ▼|HON225.02-1.31 (-0.58%) ▼|IBM212.67-6.38 (-2.91%) ▼|INTC95.04-1.94 (-2.00%) ▼|INTU291.09-3.70 (-1.26%) ▼|ISRG345.42-56.91 (-14.15%) ▼|JNJ253.04+3.07 (+1.23%) ▲|JPM341.10-2.05 (-0.60%) ▼|KO81.56-3.36 (-3.96%) ▼|LIN513.22-7.52 (-1.44%) ▼|LLY1,179.11+9.94 (+0.85%) ▲|LMT508.77-4.75 (-0.93%) ▼|LOW208.73-7.43 (-3.44%) ▼|LRCX313.30-7.66 (-2.39%) ▼|MA543.60-7.94 (-1.44%) ▼|MCD267.71-5.75 (-2.10%) ▼|MDLZ61.00-0.42 (-0.68%) ▼|MDT83.20-0.36 (-0.43%) ▼|META646.01-18.53 (-2.79%) ▼|MMM159.84-1.93 (-1.19%) ▼|MO74.21+1.18 (+1.62%) ▲|MRK127.50-0.13 (-0.10%) ▼|MS215.50-2.87 (-1.31%) ▼|MSFT393.82-7.28 (-1.82%) ▼|MU848.95-4.25 (-0.50%) ▼|NEE88.80-0.55 (-0.62%) ▼|NFLX68.95-5.40 (-7.26%) ▼|NKE43.76-0.81 (-1.82%) ▼|NOW103.24-0.77 (-0.74%) ▼|NVDA202.81-4.59 (-2.21%) ▼|ORCL126.41+2.20 (+1.77%) ▲|PEP137.12-2.31 (-1.66%) ▼|PFE25.05-0.09 (-0.36%) ▼|PG149.98-1.52 (-1.00%) ▼|PLTR132.38-2.06 (-1.53%) ▼|PM192.98+3.14 (+1.65%) ▲|QCOM171.78+1.11 (+0.65%) ▲|RTX193.51-0.85 (-0.44%) ▼|SBUX105.49-2.88 (-2.66%) ▼|SCHW101.56-1.24 (-1.21%) ▼|SO95.30-0.77 (-0.80%) ▼|SPG228.70+0.21 (+0.09%) ▲|T21.81-0.17 (-0.77%) ▼|TMO532.48-10.71 (-1.97%) ▼|TMUS192.43-0.42 (-0.22%) ▼|TSLA380.84-10.22 (-2.61%) ▼|TXN284.02-7.20 (-2.47%) ▼|UBER72.46-1.58 (-2.13%) ▼|UNH426.09+2.71 (+0.64%) ▲|UNP301.75+2.33 (+0.78%) ▲|UPS117.72+0.54 (+0.46%) ▲|USB63.14-0.87 (-1.36%) ▼|V358.56-6.58 (-1.80%) ▼|VZ43.59-0.29 (-0.66%) ▼|WFC87.51-0.56 (-0.64%) ▼|WMT114.24-0.71 (-0.62%) ▼|XOM147.36+1.41 (+0.97%) ▲|
22.8 C
New York
Saturday, July 18, 2026

Tag: quarterly report

Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc

Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination

Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference

SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced positive five-year data from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the Company’s lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD). The data will be presented at the Parent Project Muscular Dystrophy (PPMD) 2026 Annual Conference, taking place June 25-27, 2026, in Orlando, Florida, alongside previously reported results from the Company’s HOPE-3 Phase 3 trial.

Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes

NEW YORK, June 25, 2026 Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges...

Eikon Therapeutics to Join the Russell 3000® Index

Addition reflects Eikon's progress as a publicly traded company and increasing visibility within the investment community
Addition reflects Eikon's progress as a publicly traded company and increasing visibility within the investment community

uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

LEXINGTON, Mass. and AMSTERDAM, June 25, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of its previously announced underwritten public offering of 5,686,813 ordinary shares at a public offering price of $45.50 per share, which includes 741,758 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary shares in the offering. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by uniQure, were approximately $259 million. All securities in the offering were sold by uniQure.

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an underwritten public offering of 32,500,001 shares of its common stock at a price to the public of $6.00 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 833,333 shares of its common stock at an offering price of $5.999 per pre-funded warrant, in each case before underwriting discounts and commissions. All of the securities are being offered by Taysha. In addition, Taysha has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering to Taysha are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and other offering expenses, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about June 26, 2026, subject to customary closing conditions.

Chemours Reaches Agreement with U.S. EPA to Resolve Claims Relating to PFAS

The settlement resolves the federal government's claims relating to discharge of PFAS compounds across three current operating sites, as well as certain environmental claims...

SPHERE AX Partners with U.S. AI Semiconductor Company Blaize at the National Assembly

Korea-U.S. Physical AI Cooperation Gets Underway -- Joint Development of AI Semiconductor-Based ProductsEL DORADO HILLS, Calif. and SEOUL, South Korea, June 24, 2026 /PRNewswire/...

Teva Releases Q2 2026 Aide Memoire

TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2026 Aide Memoire is available on the “Investors” page on its website.

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ecopipam, a first-in-class investigational therapy for the treatment of pediatric Tourette syndrome.

Ribbon and Comporium Expand Partnership to Advance Voice Infrastructure Modernization

Delivers scalable, future-ready IP voice platformPLANO, Texas, June 18, 2026 /PRNewswire/ -- Ribbon Communications Inc. (Nasdaq: RBBN), a global leader in real-time communications technology and...

Enphase Energy Begins Shipments of GaN-Based 548 VA IQ9S Commercial Microinverters in the United States

FREMONT, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company, today announced that it began production shipments of its IQ9S-3P™ Commercial Microinverter, the company's most powerful microinverter currently available across the United States. Built with advanced gallium nitride (GaN) technology, the IQ9S-3P Commercial Microinverter supports high-wattage solar panels up to 770 W and connects directly to three-phase 480Y/277 V (wye) grid configurations without requiring external transformers.

Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Reported positive clinical proof-of-concept data for OD-001 in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis.

PodcastOne (Nasdaq: PODC) to Announce Its Fiscal Year 2026 Financial Results

LOS ANGELES, June 17, 2026 (GLOBE NEWSWIRE) -- PodcastOne (Nasdaq: PODC), a leading publisher and podcast sale network plans to announce its operating and financial results for the fiscal year ended March 31, 2026 (“Fiscal Year 2026”) and host an investor webcast to discuss the results and provide a business update on Wednesday, June 24, 2026 at 12:30 pm Eastern Time (9:30 am Pacific Time).

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsQuarterly report